IP Library Granted Patent US 8,080,643
Granted Patent B2
US 8,080,643 · App. 11/850,191 · Granted Dec 20, 2011

HPV primers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,080,643
App. No.
11/850,191
Granted
Dec 20, 2011
Kind
B2
Abstract

The present invention provides methods, kits, and compositions related to human papillomavirus (HPV) primers, which may be used, for example, in nucleic acid detection assays for use in basic research, clinical research, and for the development of clinical detection assays.

Claims (10)

1. A composition configured to hybridize to target nucleic acids from a plurality of different HPV types, said composition comprising an isolated nucleic acid sequence, wherein the nucleotide sequence of said isolated nucleic acid sequence consists of SEQ ID NO:142 or SEQ ID NO:143.

2. The composition of claim 1 , further comprising a second isolated nucleic acid sequence different from said isolated nucleic acid sequence, wherein the nucleotide sequence of said second isolated nucleic acid sequence consists of SEQ ID NO:142 or SEQ ID NO:143.

3. The composition of claim 1 , further comprising at least 20 additional isolated nucleic acid sequences, wherein the nucleotide sequences of said additional isolated nucleic acid sequences each consist of a nucleotide sequence shown in SEQ ID NOs:1-123 and 142-154.

4. A kit comprising a composition configured to hybridize to target nucleic acids from a plurality of different HPV types, said composition comprising an isolated nucleic acid sequence, wherein the nucleotide sequence of said isolated nucleic acid sequence consists of SEQ ID NO:142 or SEQ ID NO:143.

5. The kit of claim 4 , wherein said composition further comprises a second isolated nucleic acid sequence different from said isolated nucleic acid sequence, wherein the nucleotide sequence of said second isolated nucleic acid sequence consists of SEQ ID NO:142 or SEQ ID NO:143.

6. The kit of claim 4 , further comprising at least 20 additional isolated nucleic acid sequences, wherein the nucleotide sequences of said additional isolated nucleic acid sequences each consist of a nucleotide sequence shown in SEQ ID NOs:1-123 and 142-154.

7. A method for detecting at least one HPV sequence in a sample, comprising using a composition configured to hybridize to target nucleic acids from a plurality of different HPV types, said composition comprising an isolated nucleic acid sequence, wherein the nucleotide sequence of said isolated nucleic acid sequence consist of SEQ ID NO:142 or SEQ ID NO:143.

8. The method of claim 7 , wherein said detecting allows typing of said HPVsequence.

9. The method of claim 7 , wherein said using comprises sequencing with said nucleic acid sequence.

10. The method of claim 7 , wherein said using comprises amplifying said HPV sequence with said nucleic acid sequence.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
MERGER Recorded Oct 23, 2015
From: THIRD WAVE AGBIO, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: GEN-PROBE INCORPORATED
Reel/Frame 036934/0796 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 26, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024892/0001 →
SECURITY AGREEMENT Recorded Jul 29, 2008
From: THIRD WAVE TECHNOLOGIES, INC.
To: GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT
Reel/Frame 021301/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2008
From: KING, JOSEPH J.; HUDSON, ANGELA
To: THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 020769/0058 →